By Chris Wack

Anaptys said Monday that it saw positive top-line results from its global Phase 3 trial evaluating the safety and efficacy of imsidolimab in patients with generalized pustular psoriasis flares.

The stock was halted at $19.25 in premarket trading.

The biotechnology company said that investigational imsidolimab met its primary endpoint in the study population achieving rapid clearance of pustulation, erythema and scaling after a single dose of 750mg IV imsidolimab.

Top-line data also demonstrate a favorable safety and tolerability profile.

All adverse effects reported in imsidolimab-treated patients were mild or moderate and balanced across imsidolimab-treated versus placebo patients. No serious or severe adverse effects were reported in imsidolimab-treated patients.

Anaptys plans to present comprehensive data from the trial in the second half of 2024. The company anticipates filing a biologics license application with the U.S. Food and Drug Administration by the third quarter of 2024.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

October 09, 2023 08:28 ET (12:28 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more AnaptysBio Charts.
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more AnaptysBio Charts.